The agency has approved the combination of tremelimumab (Imjudo) and durvalumab (Imfinzi) for use together with chemotherapy for patients with metastatic non–small cell lung cancer (mNSCLC).
FDA Approvals
The agency has approved the combination of tremelimumab (Imjudo) and durvalumab (Imfinzi) for use together with chemotherapy for patients with metastatic non–small cell lung cancer (mNSCLC).
FDA Approvals